Pharmaceutical

Revolution of Radiopharmaceuticals: From Diagnosis to Treatment Radiopharmaceuticals Transformative impact of radiopharmaceuticals in modern medicine. Discover how these advanced drugs are revolutionizing cancer diagnosis and treatment, merging imaging with targeted therapy for personalized patient care. With the market projected to grow to $14 billion by 2032.
Pfizer RSV Vaccine Approval Pfizer FDA Pfizer's RSV vaccine, Abrysvo, has received FDA approval for use in high-risk adults aged 18-59, expanding its reach beyond older adults and pregnant women. This decision follows a successful Phase III trial, promising enhanced protection against respiratory syncytial virus (RSV) infections.
$1.3 Billion! Merck Acquires a Biotech Company Merck Modifi Bio Merck has acquired Modifi Biosciences for up to $1.3 billion, securing rights to its experimental cancer therapy, KL-50, aimed at treating hard-to-treat brain tumors like gliomas. This deal includes a $30 million upfront payment, with potential milestone payments.
Next Domestic Big Drug Astellas FDA Astellas has secured FDA approval for Zolbetuximab, the first Claudin18.2-targeted antibody for advanced HER2-negative gastric cancer. This breakthrough opens a new market, addressing a critical need in cancer treatment and forecasting substantial sales growth in the coming years.
"Old Money" BMS, Eager to Earn New Money Bristol Myers Squibb Bristol Myers Squibb (BMS) is striving to break its slump with FDA approval of its schizophrenia drug Kar-XT, marking a critical turning point. With forecasted sales of $3.1 billion by 2030, BMS aims to rebound despite recent challenges, including layoffs and patent cliffs.
Biotech Revives Regeneron's Old Drug Kiniksa Pharmaceuticals Kiniksa Pharmaceuticals has revitalized Regeneron’s ARCALYST, driving sales up by 30x since 2020. Originally launched in 2008, the drug is now the first FDA-approved treatment for recurrent pericarditis, achieving $233.2M in 2023 sales with projections reaching up to $415M in 2024.
China's First! BeiGene's PD-1 Inhibitor Baizean® Approved for 14th Indication BeiGene BeiGene's PD-1 inhibitor Baizean® (Tislelizumab) has been approved in China for its 14th indication, marking it as the first PD-1 drug for perioperative immunotherapy in stage II-III non-small cell lung cancer. This new treatment improves event-free survival, offering hope for better outcomes.
Gilead: Trial Failure, Withdraws Approval of Trodelvy for Bladder Cancer Treatment Gilead Gilead has voluntarily withdrawn Trodelvy's accelerated approval for bladder cancer after a failed confirmatory trial. While the drug's effectiveness in other cancers remains unaffected, the failure casts a shadow on its future, as competitors advance in the TROP2 ADC market.
5 Strategies to Make New Drugs Surpass Their Predecessors Five strategies to outperform first-in-class (FIC) drugs and achieve best-in-class (BIC) status. From identifying new indications and enhancing selectivity to optimizing pharmacokinetics and developing dual-function molecules.
FDA approves AbbVie's 24-hour subcutaneous infusion therapy AbbVie FDA The FDA has approved AbbVie’s VYALEV (ABBV-951), a 24-hour continuous subcutaneous infusion therapy for advanced Parkinson's disease. This first-of-its-kind treatment, based on levodopa, offers significant improvements in motor fluctuations and prolongs "on" time with fewer complications.